Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Merck Serono S.A.. (12/21/10). "Press Release: Merck Serono and Philochem Enter into Research Agreement in Fertility". Geneva.

Organisations Organisation Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Organisation 2 Philogen S.p.A.
  Group Philogen (Group)
Products Product women’s health
  Product 2 prenatal test
Person Person Kirschbaum, Bernhard (Merck Serono 200809 Executive VP Research)
     


Merck Serono, the pharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced a strategic agreement with Philochem AG, Switzerland, the research unit of Philogen S.p.A., Italy. Under the terms of the agreement, Philochem will supply specific monoclonal antibodies to Merck Serono, to be used in the search for molecular biomarkers of oocyte and embryo quality. Further terms of the agreement are not disclosed.

Once validated, molecular biomarkers can be used for the development of predictive or diagnostic tests that can help physicians assess objectively oocyte and embryo quality.

"We are convinced that the development of innovative non-invasive diagnostic tests to evaluate oocyte and embryo quality could help In Vitro Fertilization specialists offer infertile couples the best chance of achieving their dream of having a baby on their own," said Bernhard Kirschbaum, Executive Vice President, Head of Global Research and Development at Merck Serono.

“Philochem has a considerable track record in the isolation of specific binding molecules. We are delighted to enter into this collaborative agreement with Merck Serono in the area of fertility and we look forward to contributing to the advancement of In Vitro Fertilization techniques,” said Dr. Eveline Trachsel, Director of Research, at Philochem AG.

Merck Serono is the world leader in fertility treatments. The company’s vision is to develop and provide innovative, easy-to-use products and devices, as well as new technologies to help infertile couples at every stage of the reproductive cycle: from follicular development to early pregnancy.

About Merck Serono and Fertility Treatment

Merck Serono is the world leader in fertility treatments, and the only company to offer a full portfolio of fertility drugs for every stage of the reproductive cycle and recombinant versions of the three hormones needed to treat infertility: GONAL-f® (follitropin alfa), to stimulate the ovaries and produce eggs in women and spermatogenesis induction in men; Luveris® (lutropin alfa), to stimulate follicular development in women who are profoundly LH deficient; Ovitrelle® (choriogonadotropin alfa), to help follicles mature and release eggs; Pergoveris® (follitropin alfa/lutropin alfa) to stimulate follicular development in women with severe LH and FSH deficiency; Cetrotide® (cetrorelix acetate) to prevent a premature ovulation; and Crinone® (progesterone gel), to help establish and maintain a pregnancy. Not all products are available in all markets.


About Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.

Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets.

With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in rheumatology.


About Merck

Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees.

Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merck.de

   
Record changed: 2017-04-02

Advertisement

Picture [LSS] Life-Sciences-Scandinavia.com – The Business Web Portal 560x95px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top